{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T14:19:42Z","timestamp":1772547582439,"version":"3.50.1"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Lacosamide is a novel anticonvulsant that acts by enhancing sodium channel slow inactivation. The aims of this study were to evaluate the influence of concomitant antiepileptic drugs (AEDs) on serum lacosamide concentration and explore the relationship between lacosamide serum concentration and both clinical response and adverse effects.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The authors analyzed 649 serum samples from 426 Japanese patients with epilepsy. The concentration-to-dose (CD) ratio of lacosamide was compared among patients on various AED regimens. Clinical information about seizure frequency and adverse events was obtained from clinical records.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>In patients who did not receive enzyme-inducing AEDs, the CD ratio (mean \u00b1 SD) of lacosamide was 1.84 \u00b1 0.68. By contrast, the CD ratio in patients who received phenytoin, carbamazepine, and phenobarbital was 1.42 \u00b1 0.66 (22.8% lower), 1.46 \u00b1 0.40 (20.7% lower), and 1.36 \u00b1 0.38 (26.1% lower), respectively. Seventy-four patients (17.3%) achieved &gt;50% seizure reduction. The median lacosamide concentration in patients who received and did not receive a sodium channel blocker was 6.6 mcg\/mL (26.4 \u03bcmol\/L) and 8.4 mcg\/mL (33.6 \u03bcmol\/L), respectively. Adverse events, including dizziness, somnolence, diplopia, and anorexia, were reported by 70 patients (16.4%). The incidence rate in patients treated with sodium channel blockers was significantly higher than that in patients not treated with these drugs (21.1% vs. 10.3%; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.005), and the median lacosamide concentration in these patient groups was 5.1 (20.4 \u03bcmol\/L) and 7.5 mcg\/mL (30 \u03bcmol\/L), respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Therapeutic drug monitoring of lacosamide is clinically useful because it allows physicians to estimate the extent of drug interactions and adjust the dose in individual AED regimens.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000764","type":"journal-article","created":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T23:35:39Z","timestamp":1588635339000},"page":"754-759","source":"Crossref","is-referenced-by-count":14,"title":["Therapeutic Monitoring of Lacosamide in Japanese Patients With Epilepsy: Clinical Response, Tolerability, and Optimal Therapeutic Range"],"prefix":"10.1097","volume":"42","author":[{"given":"Yoshiaki","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Department of Clinical Research, NHO, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Urushiyama;"},{"name":"Department of Clinical Pharmaceutics, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Yada; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyohito","family":"Terada","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, NHO, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Urushiyama;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasukiyo","family":"Araki","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, NHO, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Urushiyama;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaro","family":"Fukushima","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, NHO, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Urushiyama;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsumi","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, NHO, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Urushiyama;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Kagawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmaceutics, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Yada; and"},{"name":"Laboratory of Clinical Pharmacokinetics and Drug Safety, Shizuoka General Hospital, Kita Ando, Shizuoka, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukitoshi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, NHO, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Urushiyama;"},{"name":"Department of Clinical Pharmaceutics, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Yada; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230928","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.nurt.2006.10.002","article-title":"Lacosamide","volume":"4","author":"Giraud Doty","year":"2007","journal-title":"Neurotherapeutics."},{"key":"R2-20230928","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2165\/00023210-200923070-00002","article-title":"Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders","volume":"2","author":"Curia","year":"2009","journal-title":"CNS Drugs."},{"key":"R3-20230928","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s40262-015-0276-0","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of lacosamide","volume":"54","author":"Cawello","year":"2015","journal-title":"Clin Pharmacokinet."},{"key":"R4-20230928","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1097\/FTD.0b013e318290eacc","article-title":"Lacosamide therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs","volume":"35","author":"Contin","year":"2013","journal-title":"Ther Drug Monit."},{"key":"R5-20230928","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/FTD.0000000000000051","article-title":"Lacosamide serum concentrations in adult patients with epilepsy: the influence of gender, age, dose, and concomitant antiepileptic drugs","volume":"36","author":"Markoula","year":"2014","journal-title":"Ther Drug Monit."},{"key":"R6-20230928","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1007\/s11064-017-2234-8","article-title":"Therapeutic drug monitoring of lacosamide in Norway: focus on pharmacokinetic variability, efficacy and tolerability","volume":"42","author":"Svendsen","year":"2017","journal-title":"Neurochem Res."},{"key":"R7-20230928","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1528-1167.2007.01188.x","article-title":"Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures","volume":"48","author":"Ben-Menachem","year":"2007","journal-title":"Epilepsia."},{"key":"R8-20230928","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1528-1167.2008.01951.x","article-title":"Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial","volume":"50","author":"Hal\u00e1sz","year":"2009","journal-title":"Epilepsia."},{"key":"R9-20230928","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther."},{"key":"R10-20230928","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","article-title":"Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update","volume":"40","author":"Patsalos","year":"2018","journal-title":"Ther Drug Monit."},{"key":"R11-20230928","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/FTD.0000000000000274","article-title":"Perampanel serum concentrations in adults with epilepsy: effect of dose, age, sex, and concomitant anti-epileptic drugs","volume":"38","author":"Patsalos","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R12-20230928","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s00228-014-1719-5","article-title":"Impact of cytochrome P450 inducers with or without inhibitors on the serum clobazam level in patients with antiepileptic polypharmacy","volume":"70","author":"Yamamoto","year":"2014","journal-title":"Eur J Clin Pharmacol."},{"key":"R13-20230928","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/FTD.0000000000000518","article-title":"Comparison of CYP3A4-inducing capacity of enzyme-inducing antiepileptic drugs using 4\u03b2-hydroxycholesterol as biomarker","volume":"40","author":"Hole","year":"2018","journal-title":"Ther Drug Monit."},{"key":"R14-20230928","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000336774","article-title":"Pharmacokinetics of lacosamide in healthy Korean male volunteers","volume":"89","author":"Kim","year":"2012","journal-title":"Pharmacology."},{"key":"R15-20230928","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2133\/dmpk.18.48","article-title":"Bioinformatics research on inter-racial difference in drug metabolism I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19","volume":"18","author":"Shimizu","year":"2003","journal-title":"Drug Metab Pharmacokinet."},{"key":"R16-20230928","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/ane.13206","article-title":"Clinical experience combined with therapeutic drug monitoring of lacosamide","volume":"141","author":"Svendsen","year":"2020","journal-title":"Acta Neurol Scand."},{"key":"R17-20230928","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1528-1167.2012.03589.x","article-title":"The adverse event profile of lacosamide: a systematic review and meta-analysis of randomized controlled trials","volume":"54","author":"Zaccara","year":"2013","journal-title":"Epilepsia."},{"key":"R18-20230928","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/11587550-000000000-00000","article-title":"A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs","volume":"24","author":"Sake","year":"2010","journal-title":"CNS Drugs."},{"key":"R19-20230928","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/epi.13466","article-title":"Lacosamide use in children with epilepsy: retention rate and effect of concomitant sodium channel blockers in a large cohort","volume":"57","author":"McGinnis","year":"2016","journal-title":"Epilepsia."},{"key":"R20-20230928","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1111\/epi.13869","article-title":"Lacosamide in the treatment of patients with epilepsy and intellectual disabilities: a long-term study of 136 patients","volume":"58","author":"B\u00f6ttcher","year":"2017","journal-title":"Epilepsia."},{"key":"R21-20230928","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/epi4.12346","article-title":"Changes in drug load during lacosamide combination therapy: a noninterventional, observational study in German and Austrian clinical practice","volume":"4","author":"Reinhardt","year":"2019","journal-title":"Epilepsia Open."},{"key":"R22-20230928","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.seizure.2019.01.027","article-title":"Switching from traditional sodium channel blockers to lacosamide in patients with epilepsy","volume":"65","author":"Kim","year":"2019","journal-title":"Seizure."},{"key":"R23-20230928","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1528-1167.2012.03671.x","article-title":"Enzyme induction with antiepileptic drugs: cause for concern?","volume":"54","author":"Brodie","year":"2013","journal-title":"Epilepsia."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000764","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T01:05:48Z","timestamp":1695863148000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000764","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}